GL Pharm Tech KRX:204840KOSDAQ
지엘팜텍 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked10since Sep 11
In Q2 2026, GL Pharm Tech reported revenue of ₩9.7bn, up 16.1% year on year, and operating profit of ₩231m. GL Pharm Tech (지엘팜텍) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
GL Pharm Tech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩9.7bn | +16.1% | ₩231m margin 2.4% | ₩82m |
| Q1 2026 | ₩9.4bn | +20.3% | ₩35m margin 0.4% | −₩120m |
| Q4 2025 derived | ₩9.5bn | +11.3% | −₩294m margin −3.1% | −₩201m |
| Q3 2025 | ₩9.5bn | +103.7% | ₩253m margin 2.6% | ₩133m |
| Q2 2025 | ₩8.4bn | +20.0% | ₩182m margin 2.2% | ₩57m |
| Q1 2025 | ₩7.8bn | +34.4% | ₩128m margin 1.6% | ₩24m |
| Q4 2024 derived | ₩8.6bn | +15.5% | ₩43m margin 0.5% | ₩93m |
| Q3 2024 | ₩4.7bn | -39.1% | ₩138m margin 3.0% | −₩118m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
GL Pharm Tech top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.